Active substanceBicalutamideBicalutamide
Similar drugsTo uncover
  • Androblock®
    pills inwards 
  • Balutar®
    pills inwards 
    TAD Pharma GmbH     Germany
  • Bicalutamide
    pills inwards 
    BIOCAD, CJSC     Russia
  • Bicalutamide
    pills inwards 
    ATOLL, LLC     Russia
  • Bicalutamide
    pills inwards 
    BIOCAD, CJSC     Russia
  • Bicalutamide
    pills inwards 
  • Bicalutamide
    pills inwards 
  • Bicalutamide
    pills inwards 
  • Bicalutamide Grindeks
    pills inwards 
    GRINDEX, JSC     Latvia
  • Bicalutamide Cabi
    pills inwards 
  • Bicalutamide Canon
    pills inwards 
  • Bicalutamide Sandoz®
    pills inwards 
    Sandoz d.     Slovenia
  • Bicalutamide-Siguardis
    pills inwards 
    SIGARDIS ENG, LLC     Russia
  • Bicalutamide-Teva
    pills inwards 
  • Bicutulter
    pills inwards 
  • Bicutulter
    pills inwards 
  • Bicane®
    pills inwards 
    NATIVA, LLC     Russia
  • Bikaprost®
    pills inwards 
  • Bilumide®
    pills inwards 
    VEROPHARM SA     Russia
  • Bilumide®
    pills inwards 
    VEROPHARM SA     Russia
  • Calumid®
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Calumid®
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Casodex®
    pills inwards 
    AstraZeneca UK Ltd     United Kingdom
  • Casodex®
    pills inwards 
    AstraZeneca UK Ltd     United Kingdom
  • Dosage form: & nbspfilm-coated tablets
    Composition:

    1 tablet, film-coated, contains:

    active substance: bicalutamide 50.00 mg;

    Excipients: lactose monohydrate 132.00 mg, sodium carboxymethyl starch 12.50 mg, povidone-K30 5.00 mg, magnesium stearate 0.50 mg;

    shell: opadrai II (33F28627) 6.00 mg (composition: hypromellose-2910, lactose monohydrate, titanium dioxide (E171), macrogol-3000).
    Description:Round, biconvex tablets covered with a film membrane, white or almost white; on one side of the tablet there is an engraving "485". White or almost white in cross-section.
    Pharmacotherapeutic group:antitumor agent - antiandrogen
    ATX: & nbsp

    L.02.B.B.03   Bicalutamide

    Pharmacodynamics:

    Antitumor drug, antiandrogenic nonsteroid drug.

    Bicalutamide is a racemic mixture with non-steroidal antiandrogenic activity predominantly (R) -enantiomer, does not have a different endocrine activity. Bicalutamide binds to androgen receptors and, without activating the expression of genes, suppresses the stimulating effect of androgens. The result is regression of malignant neoplasms of the prostate gland.

    In some patients, discontinuing bicalutamide may lead to the development of a clinical "anti-androgen withdrawal syndrome".

    Pharmacokinetics:

    Suction and distribution

    After oral administration, it is quickly and completely absorbed from the gastrointestinal tract. Eating does not affect absorption.

    With daily intake of bicalutamide, the concentration (R) -enantiomer in plasma increases approximately 10-fold due to prolonged T1/2, which makes it possible to take the drug 1 time / day. With a daily intake of bicalutamide in a dose of 50 mg Css (R) -enantiomer in plasma is about 9 μg / ml. When taking 150 mg of bicalutamide daily Css (R) -enantiomer is about 22 μg / ml. At an equilibrium state, about 99% of all enantiomers circulating in the blood is active (R) -enantiomer.

    The binding with plasma proteins is high (for a racemic mixture of 96%, for the (R) - enantiomer of 99.6%).

    Metabolism and excretion

    Intensively metabolized in the liver (by oxidation and the formation of conjugates with glucuronic acid). Metabolites are excreted in urine and bile approximately in equal proportions.

    (S) -enantiomer is eliminated from the body much faster (R) -enantiomer, T1/2 the last - about 7 days.

    Pharmacokinetics in special clinical cases

    The pharmacokinetics of the (R) -enantiomer are not affected by age, renal dysfunction, mild or moderate hepatic impairment. There is evidence that in patients with severe impairment of liver function, elimination is slowed (R) -enantiomer from the plasma.

    Indications:

    - Bicalutamide in a dose of 50 mg in combination with an analogue of GnRH (gonadotropin-releasing hormone) or surgical castration is indicated for the treatment of advanced prostate cancer.

    - Bicalutamide in a dose of 150 mg is indicated for the treatment of locally advanced prostate cancer (T3-T4, any N, M0, T1-T2, N +, M0) as monotherapy or adjuvant therapy in combination with radical prostatectomy or radiotherapy.

    - Bicalutamide in a dose of 150 mg is also indicated for the treatment of locally advanced, non-metastatic prostate cancer in cases where surgical castration or other medical interventions are unacceptable or not applicable.

    Contraindications:

    - Simultaneous reception with terfenadine, astemizole and cisapride;

    - Hypersensitivity to bicalutamide and auxiliary components of the drug.

    Bicalutamide should not be given to children and women.

    Carefully:

    When the liver function is impaired; lactose intolerance, lactase deficiency or malabsorption of glucose / galactose.

    Pregnancy and lactation:

    Bicalutamide can not be administered during pregnancy and lactation.

    The result of the application of bicalutamide to pregnant rats was the feminization of male offspring accompanied by anaspadia, regardless of the dose.
    Dosing and Administration:

    Inside, regardless of food intake, it is desirable at the same time.

    Adults and older men:

    With advanced prostate cancer in combination with the GnRH analogue (gonadotropin-releasing hormone) or surgical castration inside by 50 mg once a day.Treatment with bicalutamide should begin at the same time as the beginning of the GnRH analogue or surgical castration.

    With locally advanced prostate cancer: inside 150 mg once a day. Bicalutamide should be taken for a long time, at least for 2 years. If signs of disease progression appear, the drug should be discontinued.

    Patients with impaired renal function:

    Do not change the dosage regimen.

    Patients with impaired hepatic function:

    Do not change the dosage regimen. It is possible to increase the cumulation of the drug in patients with severe hepatic impairment.

    Side effects:

    The pharmacological action of bicalutamide can cause the following side effects:

    Often (> 10%): gynecomastia (may persist even after discontinuation of therapy, especially if the drug is taken for a long time, tenderness of the mammary glands, "flushes" of blood to the face, decreased sexual desire, sexual dysfunction;

    Often (≥1%, but <10%): diarrhea, nausea, transient increase in hepatic transaminase activity,cholestasis and jaundice (these changes in liver function were rarely estimated as serious, transient, completely disappeared or decreased with continued therapy or after withdrawal), itching, asthenia; when using the drug in a daily dose of 150 mg - alopecia or hair regrowth, weight gain.

    Rarely (≥ 0.1%, but <1%): increased sensitivity reactions, including angioedema and urticaria, interstitial lung diseases; when using the drug in a daily dose of 150 mg - abdominal pain, depression, dyspepsia, hematuria.

    Rarely (≥ 0.01%, but <0.1%): vomiting, dry skin (with the use of the drug in a daily dose of 150 mg, dry skin is often observed), liver failure, (the cause-and-effect relationship with bicalutamide is not established).

    With the simultaneous use of bicalutamide and GnRH analogues, the following adverse events with a frequency of ≥ 1% can also be observed (a causal relationship with the administration of the drug has not been established, some of the noted side effects have been observed in elderly patients):

    From the side of the cardiovascular system: heart failure, stenocardia, conduction disorders, including lengthening PR and QT intervals, rhythm disturbances, nonspecific changes in the ECG, increased blood pressure, myocardial infarction, syncope.

    From the digestive system: gastric bleeding, anorexia, dry mouth, indigestion, constipation, flatulence, periodontal abscess, gastric / intestinal cancer.

    From the nervous system: dizziness, headache, insomnia, anxiety, drowsiness, neuropathy.

    From the respiratory system: shortness of breath, chest pain, cough, pharyngitis, bronchitis, pneumonia, rhinitis, bronchospasm, nosebleeds.

    From the urinary system: nocturia, dysuria, urinary retention, swelling, frequent urination, hydronephrosis, infection.

    On the part of the hematopoiesis system: anemia.

    Dermatological reactions: alopecia, skin rash, increased sweating, hirsutism, dry skin, herpetic infection, skin cancer.

    From the musculoskeletal system: myasthenia gravis, myalgia, convulsions, arthritis, joint contractures, bone pain, leg cramps.

    From the laboratory indicators: hyperglycemia, increased activity of AP, hypercreatininaemia, hypercholesterolemia, hyperbilirubinemia.

    Other: diabetes, polyuria, increased or decreased body weight, abdominal, breast, pelvic pain, sexual dysfunction, development of the tumor process, chills, dehydration, gout, cataract.

    Overdose:

    There are no data on cases of drug overdose in humans.

    Treatment symptomatic. There is no specific antidote. Dialysis is ineffective, because bicalutamide is highly bound to plasma proteins and is not found in urine in unchanged form. Shows general measures, including monitoring of vital parameters of the heart and respiratory organs.

    Interaction:

    There is no evidence of pharmacokinetic or pharmacodynamic interactions between bicalutamide and GnRH analogues (gonadotropin-releasing hormone).

    In studies in vitro shown, that (R) enantomer of bicalutamide inhibits the CYP 3A4 isoenzyme, to a lesser extent affecting the activity of the CYP 2C9, 2C19, and 2D6 isoenzymes. The potential for bicalutamide to interact with other drugs has not been revealed, however, when bicalutamide is used for 28 days with midazolam, the area under the midazolam AUC curve increases by 80%.

    Incompatible with terfenadine, astemizole, cisapride.

    Caution should be exercised in prescribing bicalutamide simultaneously with cyclosporine or calcium channel blockers. It may be necessary to reduce the dose of these drugs, especially in the case of potentiation or the development of side effects. After the beginning of the use or elimination of bicalutamide, it is recommended that the concentration of cyclosporin in the plasma be carefully monitored and the patient's clinical condition monitored.

    The simultaneous use of bicalutamide and drugs that inhibit microsomal oxidation of drugs, for example with cimetidine or ketoconazole, can lead to an increase in plasma bicalutamide concentration and, possibly, an increase in the incidence of side effects.

    Strengthens the effect of anticoagulants coumarin series, warfarin (competition for the connection with proteins).

    Special instructions:

    Rare deaths or hospitalizations associated with bicalutamide were documented after the drug was released to the market in people with severe liver disorders. Hepatotoxicity was observed in the first three to four months of admission.Hepatitis or a significant increase in hepatic enzymes, causing the need for drug withdrawal, were observed in 1% of patients.

    The level of transaminases in the blood plasma should be measured before the start of bicalutamide treatment, and also regularly during the first four months of treatment and some time after. When there are symptoms of hepatic dysfunction, it is necessary to immediately measure the level of transaminases in the blood plasma. When jaundice or an increase in the level of alanine transferases more than twice, stop taking bicalutamide.

    Patients with lactose intolerance must be informed that each 50 mg tablet of bicalutamide contains 132 mg of lactose monohydrate.

    In patients with progression of the disease against a background of increasing concentrations of prostate-specific antigen (PSA), consideration should be given to discontinuing drug treatment.

    It is recommended that prothrombin time be regularly monitored when bicalutamide is administered to patients receiving indirect coumarin anticoagulants.

    In patients taking GnRH agonists, a decrease in glucose tolerance was observed.This effect can lead to the development of diabetes mellitus or a decrease in glucose tolerance in patients with diabetes mellitus.

    Effect on the ability to drive transp. cf. and fur:

    Bicalutamide does not affect the ability of patients to drive vehicles or engage in other potentially hazardous activities requiring increased concentration and speed of psychomotor reactions.

    Form release / dosage:Tablets, film-coated, 50 mg.
    Packaging:

    10 tablets in a blister made of PVC film and aluminum foil. One blister along with the instructions for use are placed in a cardboard box.

    For 14 tablets in a blister made of PVC film and aluminum foil. Two blisters together with instructions for use are placed in a cardboard box.

    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:2 years.
    Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-001037
    Date of registration:21.10.2011
    Date of cancellation:2016-10-21
    The owner of the registration certificate:San Pharmaceutical Industries Co., Ltd.San Pharmaceutical Industries Co., Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspSAN PHARMACEUTICAL INDUSTRIES LTD. SAN PHARMACEUTICAL INDUSTRIES LTD. India
    Information update date: & nbsp22.11.2015
    Illustrated instructions
      Instructions
      Up